How digital therapeutics can go mainstream in fragmented U.S. healthcare

There are many stakeholders interested in digital therapeutics, but aligning under the common goal of patient needs is key.

Over the last decade, digital therapeutics have been gaining steam. In part, this shift is aided by the adoption of connected medical tools during the COVID-19 pandemic and the ongoing push toward more of a hybrid care model. However, the technologies have largely not yet hit the mainstream market.

Today, industry players are looking to get stakeholders from the provider, payer and life science industries onboard.